Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

bausch + lomb ireland limited, 3013 lake drive, citywest business campus, dublin 24, irska - травопрост - kapi za oko, otopina - 40 mikrograma/ml - urbroj: svaki ml otopine sadrži 40 mikrograma travoprosta

Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig - topotekan - uterine cervical neoplasms; small cell lung carcinoma - drugi antineoplastični agensi - monoterapija topotekan je indicirana za liječenje bolesnika s recidiviranim karcinomom pluća malih stanica (sclc) za koje ponovno liječenje s režimom prve linije ne smatra prikladnim. Топотекана u kombinaciji s цисплатином je indiciran u bolesnika s карциномой relaps grlića maternice nakon radioterapije i za pacijente sa fazi bolesti instituta svjetske banke . pacijenti s preliminarnim utjecajem cisplatinu zahtijeva dugotrajno liječenje-free interval za osnovu tretmana sa kombinacijom.

Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig - inotuzumab ozogamicin - prekursorska stanica limfoblastične leukemije-limfom - antineoplastična sredstva - besponsa je indicirana kao monoterapija za liječenje odraslih osoba s recidiviranom ili refraktornom cd22 pozitivnom akutnom limfoblastičnom leukemijom b stanica (all). odrasli bolesnici s philadelphia kromosomom pozitivnim (ph +) relapsiranim ili vatrostalnim b stanicama prekursora all trebali bi imati neuspješan tretman s najmanje 1 inhibitorom tirozin kinaze (tki).

Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig - dacomitinib monohidrat - karcinom, ne-malih stanica pluća - antineoplastična sredstva - vizimpro, kao monoterapija, je propisan za prva linija terapije kod odraslih pacijenata sa lokalno-održao ili метастатического немелкоклеточного raka pluća (НМРЛ) s epidermalnog faktora rasta (egfr) aktiviraju mutacije.

Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig - glasdegib maleate - leukemija, mieloidna, akutna - antineoplastična sredstva - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatitis, atopic - ostali dermatološki pripravci - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

roche registration gmbh - erlotinib - carcinoma, non-small-cell lung; pancreatic neoplasms - antineoplastična sredstva - Немелкоклеточный rak pluća (НМРЛ)Тарцева i ukazuje na popravak prekidača liječenja u bolesnika s lokalno-uobičajena ili metastatskih немелкоклеточным raka pluća sa egfr aktiviranje перегласовки i stabilan bolesti nakon kemoterapije prvoj liniji. Тарцева je također indiciran za liječenje bolesnika s lokalno-uobičajena ili metastatskih немелкоклеточным raka pluća nakon neuspjeha barem jedne prethodne kemoterapije shema. kod pacijenata s tumorima bez РСКФ aktiviraju mutacije, Тарцева drugačije, kada su druge mogućnosti liječenja ne raspravlja. prilikom imenovanja Тарцевы, čimbenike vezane uz dugotrajan opstanak treba uzeti u obzir. nikakva prednost opstanak ili drugi klinički značajne efekte liječenja su pokazali da je kod pacijenata sa epidermalnog faktora rasta (egfr)-ВВК - negativnih tumora. cancertarceva gušterače u kombinaciji s гемцитабином indiciran za liječenje bolesnika s metastaze raka gušterače . prilikom imenovanja Тарцевы, čimbenike vezane uz dugotrajan opstanak treba uzeti u obzir.

Europska Unija - hrvatski - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastična sredstva - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq u monoterapiji namijenjen za liječenje odraslih bolesnika s lokalno-uobičajena ili metastatskih НМРЛ nakon što je ranije kemoterapije. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq u monoterapiji namijenjen za liječenje odraslih bolesnika s lokalno-uobičajena ili metastatskih НМРЛ nakon što je ranije kemoterapije. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

mylan s.a.s., 117 allee des parcs, saint priest, francuska - travoprostum, timololum - kapi za oko, otopina - 40 mikrograma/ml + 5 mg/ml - urbroj: svaki ml otopine sadrži 40 mikrograma travoprosta i 5 mg timolola (u obliku timololmaleata)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

instituto grifols, s.a., c/can guasch, 2, pol. ind. levante, parets del valles, barcelona, Španjolska - albumin ljudski - otopina za infuziju - 200 g/l - urbroj: 1000 ml otopine za infuzju sadrži ukupno 200 g proteina, od kojeg je najmanje 95% ljudski albumin